ArticleJournal of viral hepatitis2026
Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire.
Article in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving hepatitis C virus (HCV) elimination requires innovative paradigms that overcome barriers to treatment, such as requiring pre-treatment elastography or phlebotomy-based fibrosis assessment. To identify patients at low risk of advanced fibrosis or decompensated cirrhosis within our HCV treatment programme, we developed and retrospectively assessed a clinical decision tool, the Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire (DCHEQ). Here we describe the development of DCHEQ and its test characteristics. We conducted a retrospective, nested, case-control study within a cohort of 1743 patients with HCV enrolled in an urban HCV elimination programme. The primary analysis defined cases of decompensated cirrhosis by chart review. A secondary analysis defined cases of advanced fibrosis as those with aspartate aminotransferase (AST)-platelet ratio index (APRI) > 1.5. The primary outcome was the area under the receiver operator curve (AUC) of the total DCHEQ to predict decompensated cirrhosis. We also compared the AUC of the total DCHEQ to the AUC of components of the DHEQ. For detecting cases of decompensated cirrhosis, the total of all DCHEQ items resulted in a mean AUC = 0.991 (95% CI = 0.963-1.000), which was significantly better than the discrimination of any alternative combination of DCHEQ items (p < 0.00001). For detecting cases of advanced fibrosis, the total DCHEQ score resulted in a mean AUC = 0.921 (95% CI = 0.871-0.966), which was superior to all other DCHEQ item combinations (p < 0.02). DCHEQ exhibited exquisite discrimination between cases of both decompensated cirrhosis and advanced fibrosis versus controls. After prospective validation, DCHEQ could be included in test-and-treat HCV treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.